glimepiride has been researched along with Overweight in 3 studies
glimepiride: structure given in first source
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prespecified secondary analysis of a phase IV, double-blind trial, 46 metformin-treated, overweight patients with T2D were included and randomly assigned (1:1) to once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks." | 9.34 | Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. ( Kraaijenhof, J; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; van Raalte, DH, 2020) |
| "In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks." | 9.34 | Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. ( Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH, 2020) |
| "In this prespecified secondary analysis of a phase IV, double-blind trial, 46 metformin-treated, overweight patients with T2D were included and randomly assigned (1:1) to once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks." | 5.34 | Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. ( Kraaijenhof, J; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; van Raalte, DH, 2020) |
| "In this double-blind randomized trial, 46 overweight T2DM patients without renal impairment received once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks." | 5.34 | Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. ( Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kraaijenhof, J | 1 |
| Muskiet, MHA | 2 |
| Tonneijck, L | 2 |
| Ouwens, DM | 2 |
| Kramer, MHH | 2 |
| van Raalte, DH | 2 |
| Smits, MM | 2 |
| Hartmann, B | 1 |
| Holst, JJ | 1 |
| Touw, DJ | 1 |
| Danser, AHJ | 1 |
| Joles, JA | 1 |
| Kato, H | 1 |
| Nagai, Y | 1 |
| Ohta, A | 1 |
| Tenjin, A | 1 |
| Nakamura, Y | 1 |
| Tsukiyama, H | 1 |
| Sasaki, Y | 1 |
| Fukuda, H | 1 |
| Ohshige, T | 1 |
| Terashima, Y | 1 |
| Sada, Y | 1 |
| Kondo, A | 1 |
| Sasaoka, T | 1 |
| Tanaka, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Der[NCT02106104] | Phase 4 | 48 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for glimepiride and Overweight